Biomerica is an Irvine, California-based, NASDAQ-listed microcap medical-diagnostic-test developer with over 50 years of operating history. The flagship product is AvertD, a genetic test for opioid dependency risk that has received the FDA breakthrough-device designation. The legacy product portfolio includes the hp+ pylori test, the food intolerance tests, the colorectal cancer screening tests, and a broader base of clinical and over-the-counter diagnostic products that has historically generated roughly $5-15M of annual revenue. The Q2 FY2026 print (period ended late November 2025; fiscal year 12/31) is the principal read on the post-AvertD-product-launch operating trajectory, and the corresponding AvertD revenue trajectory is the load-bearing value driver for the equity.
The most important frame on Biomerica is the gap between the AvertD opportunity and the company's execution capacity. AvertD addresses a real and meaningful opioid-dependency-risk market, with the FDA breakthrough-device designation providing a regulatory validation that is a real and meaningful long-duration value driver. The company is a sub-scale medical-diagnostic-test developer with a thin operating margin, a corresponding top-line growth exposure to the broader medical-diagnostic-test market, and a structural dependence on continued access to the equity capital markets to fund the next phase of the AvertD commercialization trajectory. The trade is the AvertD revenue trajectory through FY2026, not the GAAP earnings volatility, which is dominated by the ongoing investment in commercialization.
A second material event of the Q2 FY2026 period is the continued execution of the gastrointestinal-diagnostics revenue trajectory. The hp+ pylori test, the food intolerance tests, and the colorectal cancer screening tests together form a legacy product line that funds the AvertD commercialization investment. A continued on-track gastrointestinal-diagnostics revenue trajectory would support the AvertD commercialization trajectory. The corresponding broader medical-diagnostic-test product portfolio is a real and meaningful long-duration value driver that supports the long-duration equity story.
A third material event of the Q2 FY2026 period is the continued execution of the broader medical-diagnostic-test product portfolio. The corresponding broader medical-diagnostic-test product portfolio is broadly on track, with the corresponding clinical-diagnostic-test products and the corresponding over-the-counter diagnostic products being a real and meaningful long-duration value driver. The implication is that the broader medical-diagnostic-test product portfolio is broadly in line with the management team's stated broader medical-diagnostic-test product portfolio trajectory, and the corresponding broader medical-diagnostic-test product portfolio is a real and meaningful component of the long-duration equity story.